Homepage
IMI launches IMI2 - Call 17
New open access tools for drug development, obesity, and the environmental impacts of medicines are the focus of IMI2 - Call 17. The total budget of the Call is over EUR 80 million. Half of this comes from the European Commission’s Horizon 2020 programme and will fund the participation in the projects of universities, small and medium-sized companies, patient groups etc. The other half comes from large pharmaceutical companies and IMI Associated Partners, who do not receive EU funding through IMI but finance their own participation in our projects.
The RTCure project: a novel, preventive approach to treating rheumatoid arthritis
The RTCure project: a novel, preventive approach to treating rheumatoid arthritis more‘We brought target binding kinetics to the international research community’ – an interview with the K4DD project coordinators
‘We brought target binding kinetics to the international research community’ – an interview with the K4DD project coordinators more
IMI BROCHURE HIGHLIGHTS PROJECT SUCCESSES
IMI projects are accelerating the medicines development process, generating new scientific insights, and developing resources for open use by the research community. Furthermore, some of our projects are already delivering direct benefits to patients. Interested in concrete numbers and examples? Find out more about the impact and outputs of our projects in our new brochure, and learn how we are 'Carrying the torch for medical innovation'.
WATCH IMI video
Carrying the torch for medical innovation
Diseases keep changing, and infections we treated for decades can once again kill. By bringing together researchers from the public and private sectors, we are working to speed up medicines development and turn knowledge into treatments. Watch our video and share it!